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Irinotecan and 5-fluorouracil (5-FU) are used to treat metastatic colorectal
cancer. Irinotecan’s active metabolite is inactivated by UDP-glucuronosyl-
transferase 1A1 (UGT1A1), which is deficient in Gilbert’s syndrome.
Irinotecan and metabolites are transported by P-glycoprotein, encoded by
ABCB1. 5-FU targets folate metabolism through inhibition of thymidylate
synthase (TYMS). Methylenetetrahydrofolate reductase (MTHFR) generates
active folate necessary for haematopoiesis. We retrospectively genotyped
140 Swedish and Norwegian irinotecan and 5-FU-treated colorectal cancer
patients from the Nordic VI clinical trial for selected variants of UGT1A1,
ABCB1, TYMS and MTHFR. We found an increased risk of clinically relevant
early toxicity in patients carrying the ABCB1 3435 T/T genotype, Odds ratio
(OR)¼3.79 (95% confidence interval (CI)¼1.09–13.2), and in patients
carrying the UGT1A1*28/*28 genotype, OR¼4.43 (95% CI¼1.30–15.2).
Patients with UGT1A1*28/*28 had an especially high risk of neutropenia,
OR¼6.87 (95% CI¼1.70–27.7). Patients who had reacted with toxicity
during the first two cycles were in total treated with fewer cycles (Po0.001),
and less often responded to treatment (Po0.001). Genetic variation in
ABCB1 was associated with both early toxicity and lower response to
treatment. Carriers of the ABCB1 1236T-2677T-3435T haplotype responded
to treatment less frequently (43 vs 67%, P¼0.027), and survived shorter
time, OR¼1.56 (95% CI¼1.01–2.45).
The Pharmacogenomics Journal (2011) 11, 61–71; doi:10.1038/tpj.2010.10;
published online 23 February 2010
Keywords: camptothecin/analogs and derivatives; fluorouracil; glucuronosyltransferase;
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Introduction
Irinotecan is a camptothecin analogue used for the treatment of metastatic
colorectal cancer, either alone or in combination with 5-fluorouracil (5-FU) and
folic acid (FA). The use of irinotecan, also called CPT-11, is burdened by
unpredictable severe toxicity.
1 The main adverse reactions to irinotecan that
frequently result in dose reduction or discontinuation of treatment are severe
diarrhoea and neutropenia.
2 Other common side effects are alopecia, nausea,
vomiting and acute cholinergic-like syndrome.
Irinotecan is activated to a cytotoxic metabolite, SN-38, that inhibits the
nuclear enzyme topoisomerase 1 (TOP1), thereby blocking DNA replication.
SN-38 is primarily inactivated in the liver by the bilirubin metabolizing enzyme
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3 Mild hereditary defi-
ciency of this enzyme leads to Gilbert’s syndrome, which
is characterized by intermittent hyperbilirubinaemia. Dur-
ing phase I trials of irinotecan, a number of patients with
Gilbert’s syndrome experienced severe toxicity, suggesting
a genetic component of the reaction.
4 Subsequently, the
pharmacogenetics of irinotecan toxicity has been the focus
of several studies.
5–7
Gilbert’s syndrome is commonly caused by homozygosity
for a thymine-adenine (TA) insertion in the TATA element of
the UDP-glucuronosyltransferase 1A1 (UGT1A1) promoter.
8
This leads to seven TA repeats (the *28 allele) instead of six,
but five and eight TA repeats also occur, although rarely in
Caucasians. Inactivation of the irinotecan metabolite SN-38
is inversely correlated with the number of TA repeats, and is
significantly reduced in individuals homozygous for
UGT1A1*28.
9–11 Thus, these patients are exposed to higher
concentrations of the active metabolite, and may respond
better to treatment.
12
In an early study on the pharmacogenetics of irinotecan,
it was observed that the UGT1A1*28 allele increased the risk
of leukopenia and/or diarrhoea.
13 Although subsequent
studies have been partly conflicting,
14 most of them find a
correlation between UGT1A1*28 and haematologic toxicity
such as neutropenia.
9,15–21 Medium-to-high doses of irino-
tecan increase the risk of haematologic toxicity in *28/*28
patients according to a meta-analysis.
22 A few studies find a
correlation between UGT1A1*28 and diarrhoea
9,17,23,24 or
severe toxicity in general,
24,25 whereas others find no
correlation with toxicity at all.
26,27
As UGT1A1*28 only explains part of the toxic reactions to
irinotecan, interest has turned to other polymorphisms.
6,12
In East Asia, single nucleotide polymorphisms (SNPs) in
UGT1A1 (for example *6, *27 and *60) are more prevalent
than the TA insertion and these SNPs partly explain
irinotecan toxicity.
28–30 Genes of other glucuronidating
enzymes (UGT1A7 and UGT1A9) also contribute to irinote-
can toxicity according to a few studies.
13,26,29
Transport proteins that excrete irinotecan and metabolites
into the bile and urine have, to some extent, been
investigated for association with response and adverse
reactions to irinotecan.
6,31 P-glycoprotein, encoded by the
ATP-binding cassette gene B1 (ABCB1 or MDR1), has
rendered inconsistent results in irinotecan studies. There is
some evidence that variant genotypes and haplotypes of
ABCB1 increase the bioavailability of irinotecan and
SN-38,
32,33 while other data point in the opposite
direction.
31,34 In Korean’s, wild-type ABCB1 was associated
with neutropenia,
34 but not in an American study.
31 Neither
was any difference in toxicity or disease-free survival
observed in a French study of ABCB1 and irinotecan.
21
The uracil analogue 5-FU is often given together with
irinotecan for the treatment of metastatic colorectal cancer.
2
Only a fraction of the administered 5-FU reaches its target
cell and is transformed to active metabolites, whose mode of
action is to both inhibit the enzyme thymidylate synthase
(TYMS) and to be incorporated into RNA and DNA.
35,36
The 50untranslated region of the TYMS gene contains a
28-base-pair tandem-repeat sequence in the promoter
region, most commonly double (*2) and triple (*3) repeats.
35
The *3 allele is associated with a two- to fourfold increased
expression of TYMS compared with *2.
37 In some studies, 5-
FU-treated colorectal cancer patients carrying the *3 allele
experience better response to treatment and less toxicity,
but also the opposite has been seen.
35,38
Another enzyme implicated in the pharmacogenetics of
5-FU is methylenetetrahydrofolate reductase, encoded by
MTHFR.
35 This enzyme generates active folate necessary for
normal haematopoiesis, and reduced activity has been
associated with sensitivity to 5-FU.
39 According to some
studies, the MTHFR low activity variants 677T and 1298C
predispose to severe bone marrow toxicity in patients
treated with 5-FU.
35,38
In the randomized controlled phase III trial Nordic VI, we
compared the effects of irinotecan with either bolus 5-FU/FA
or bolus/infused 5FU/FA in patients with metastatic color-
ectal cancer.
40,41 These two schedules (FLIRI and Lv5FU2-
IRI, see below) resulted in the same overall survival (OS) and
progression-free survival (PFS, which was the primary end-
point), although response and toxicity were slightly more
favourable with the Lv5FU2-IRI schedule. In this explorative
study, we retrospectively genotyped patients from three
Nordic VI study sites in Sweden and Norway for candidate
genes in the irinotecan and 5-FU pathways and tested them
for association with toxicity, response and survival.
Materials and methods
Patients
From June 2001 to March 2004, 182 mainly Caucasian
patients with non-resectable metastatic histologically con-
firmed stage IV colorectal adenocarcinoma were included in
Uppsala and Stockholm (Sweden) and Bergen (Norway) for
the Nordic VI clinical trial.
41 Results at these three sites were
comparable to results from the 567 patients included in the
entire Nordic VI clinical trial. DNA was retrospectively
obtained from 77% of the patients from Uppsala, Stockholm
and Bergen. Blood for DNA extraction was collected from 41
surviving patients and DNA was isolated from tissue blocks
containing normal intestinal cells from 99 patients (þ6 that
were duplicates with 6 blood samples). These 140 patients
were representative for the 182 patients from the three sites
concerning pretreatment characteristics and treatment out-
come (data not illustrated).
No prior chemotherapy other than adjuvant 5-FU-based
chemotherapy completed at least 6 months before the study
entry was allowed. All patients should have measurable
disease according to the response evaluation criteria in
solid tumours (RECIST),
42 a WHO performance status of
0 to 2, adequate laboratory values, and be aged between
19 and 76 years. Elevated plasma bilirubin, X1.25 the
upper normal limit (UNL) or X1.5 UNL if liver metastases,
was an exclusion criterion. The study was performed in
accordance with the Declaration of Helsinki and Good
Clinical Practice Guidelines. The clinical trial and this
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site/country. All patients provided informed consent for the
clinical trial, and patients who donated blood provided a
separate consent.
Treatment
Patients were randomly assigned to receive irinotecan
according to the FLIRI regimen or the Lv5FU2-IRI regimen.
41
The FLIRI regimen consisted of irinotecan (Campto, Sanofi-
Aventis, Paris, France) 180mgm
 2 (initially 210mgm
 2,s e e
Glimelius et al.
40,41) as a 60mi intravenous (i.v.) infusion on
day 1, followed immediately by 5-FU 500mgm
 2 as a bolus
injection, followed by FA 60mgm
 2 i.v. bolus 30–40min
later. The Lv5FU2-IRI regimen consisted of irinotecan
180mgm
 2 i.v. infusion on day 1, followed by 5-FU bolus
400mgm
 2 and FA 200mgm
 2 as a 2h infusion, and lastly a
22-h infusion of 5-FU 600mgm
 2. With both regimens, the 5-
FU/FA administrations were repeated on day 2. All treatments
were repeated every 2 weeks until disease progression or
unacceptable toxicity. If toxicity grade 2 (except alopecia)
remained after 2 weeks, the next cycle was either delayed for
up to 2 weeks until the toxicity returned to grade 1 or the dose
was reduced by 20%. In case of grade 3–4 toxicity, irinotecan
and 5-FU doses were reduced by 20%. A second 20% reduction
was allowed if toxicity recurred at a following cycle. If doses
were reduced, they were not increased at subsequent cycles.
Concomitant medication included subcutaneous atropine
(0.25mg) as prophylaxis or treatment for severe cholinergic
symptoms. As soon as the first liquid stool occurred, oral
loperamide was administered (2mg) every 2h for at least 12h.
If diarrhoea persisted 44 8ho ri nc a s eo fs e v e r ed i a r r h o e ao r
diarrhoea associated with vomiting, fever or severe neutro-
penia, the antibiotic ciprofloxacin was administered. Patients
with febrile neutropenia were hospitalized to receive i.v.
antibiotics. Colony stimulating factor was not used.
Toxicity and response evaluation
Toxicity recorded in the case record forms was evaluated
according to the National Cancer Institute common toxicity
criteria, version 2 (http://ctep.cancer.gov/reporting/ctc.html).
  Clinically relevant early toxicity (outcome A) was regis-
tered after one or two treatment cycles. It was either grade
3–4 toxicity except alopecia or X20% dose reduction of
the following cycle or toxicity leading to 45 days delay or
discontinuation of treatment. Clinically relevant early
toxicity was the primary endpoint.
  Overall toxicity (outcome B) was any grade 3–4 toxicity
except alopecia during the entire course of therapy.
Tumour response was assessed according to RECIST.
42
Assessed outcomes were complete response (CR), partial
response (PR), stable disease (SD) and progressive disease
(PD). PFS was defined as the time from randomization to
the date of progression or death. OS was the time to death.
DNA extraction
DNA from whole blood was extracted using the QIAamp DNA
Blood Mini Kit (QIAGEN, Hinden, Germany). When whole
blood was not available, DNA was extracted from paraffin-
embedded tissue blocks containing normal intestine taken
either far (10–15cm) from the primary tumour or micro-
dissected if in proximity to the tumour. Biopsies from
Sweden were extracted using the boiling method according
to Cao et al.
43 Norwegian biopsies were extracted using the
QIAamp DNA Mini Kit protocol for paraffin-embedded
tissue (QIAGEN). Consistency of DNA quality was assessed by
extracting DNA from both blood and intestine for six patients.
Genotyping
Analysis of TA-repeat variability in the promoter region of
UGT1A1 (rs8175347) was performed using DNA fragment
analysis. Primer sequences were according to Monaghan
et al.,
8 with addition of fluorescent labelling of the forward
primer with D4 WellRed (Sigma-Aldrich, MO, USA). The
amplification reaction mixture (20ml) contained 50ng
DNA, 0.2mmoll
 1 each of deoxynucleoside triphoshate,
2,5mmoll
 1 MgCl2, 50nmoll
 1 of each primer, 0.4 U
GoTaq Flexi DNA Polymerase (Promega, WI, USA),
1 Colourless GoTaq Flexi Buffer (Promega) and 0.12gl
 1
Bovine serum albumin (Sigma-Aldrich). Polymerase chain
reaction (PCR) was performed using the thermal cycler (M.J.
Research, MN, USA) with the following temperatures: 951C
5min, 30 (951C3 0s ,5 81C4 0s ,7 21C 40s), 721C 10min,
followed by an 81C cooling step. The amplified products
were separated by capillary electrophoresis using the CEQ
8000 Genetic Analysis System (Beckman Coulter, CA, USA).
A size marker was labelled with another fluorescent colour
according to the CEQ 8000 manual. Results were analysed
using the Beckman Coulter Fragment analysis software.
Allelic discrimination of the upstream UGT1A1 -3279T4G
(rs4124874) polymorphism named *60 was performed using
the ABI 7500 FAST real-Time PCR system (Applied Bio-
systems, CA, USA) and the TaqMan Drug Metabolism
Genotyping Assay kit containing primers and probes
(C__1432134_10, Applied Biosystems).
Genotyping of three ABCB1 polymorphisms and two
MTHFR polymorphisms was performed using the ABI PRISM
7000 Sequence Detection System (Applied Biosystems).
Genotyping of ABCB1 c.2677G4T/A (rs2032582), which
leads to a change in amino acid 893 from serine to alanine
or threonine, was performed according to Saito et al.
44
Allelic discrimination of the synonymous ABCB1 poly-
morphisms c.1236C4T (rs1128503) and c.3435C4T
(rs1045642) was performed using TaqMan SNP Genotyping
Assay kits containing primers and probes (C__7586662_10
and C__7586657_1, Applied Biosystems). Genotyping of the
c.677C4T locus of MTHFR (rs1801133), which leads to a
change from amino acid alanine to valine at position 222,
was performed using a TaqMan SNP Genotyping Assay kit
containing primers and probes (C__1202883_20, Applied
Biosystems). The c.1298A4C locus of MTHFR (rs1801131),
which leads to a substitution from glutamic acid to alanine
at residue 429, was genotyped according to Robien et al.
45
The 28bp microsatellite in the 50 regulatory region of
TYMS (rs45445694) was genotyped by PCR amplification
according to Horie et al.
37 To discriminate between two (*2)
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separated by electrophoresis on 3% agarose gels.
Statistical analyses
All genotypes were checked for deviation from Hardy–
Weinberg equilibrium. Statistical analyses were performed
using the statistical program package R.
46 Associations
between genes and toxicity/response were studied through
contingency tables. Tests of homogeneity were performed
by use of Fisher’s exact test. Odds ratios (ORs) were calculated
with logistic regression. Hazard ratios (HRs) were analysed by
means of Cox regression. ABCB1 haplotypes were inferred
using PHASE, a software for haplotype reconstruction, and
recombination rate estimation from population data.
47
Results
Patients and treatment outcomes
Patient characteristics of the 140 genotyped patients are
given in Table 1. The two Nordic VI treatment groups FLIRI
Table 1 Patient characteristics, number of cycles and treatment outcome, Q1–Q3 is defined as the 1st to 3rd quartile
Characteristics FLIRI (n¼75) Lv5FU2-IRI (n¼65)
Age (years)
Mean (s.d.) 62 (7) 61 (8)
Median (range) 62 (46–75) 61 (42–76)
Gender—male, n (%) 52 (69) 37 (57)
WHO performance status, n (%)
0 47 (63) 45 (69)
1 23 (31) 16 (25)
2 3 (4) 1 (2)
Missing 2 (3) 3 (5)
Primary tumour site, n (%)
Colon 41 (55) 45 (69)
Rectum 34 (45) 20 (31)
Primary tumour resected, n (%)
Yes/no/missing 55/10/10 (73/13/13) 49/3/13 (75/5/20)
Prior adjuvant chemotherapy, n (%)
Yes/no 13/62 (17/83) 10/55 (15/85)
Location of metastases, n (%)
Liver 64 (85) 55 (73)
Lymph node 23 (35) 14 (22)
Lung 23 (31) 15 (20)
Abdominal mass 7 (11) 0 (0)
Bone 1 (1) 2 (3)
Other 17 (26) 9 (14)
No. of organs involved, n (%)
1 36 (48) 41 (63)
2 22 (29) 17 (26)
3+ 17 (23) 7 (11)
P-alkaline phosphatase 4UNL, n (%)
Yes/no/missing 42/32/1 (56/43/1) 40/24/1 (62/37/2)
Haemoglobin, mean (range), gl
 1 128 (94–171) 130 (100–161)
Low haemoglobin, n (%)
#o130gl
 1, ~ o120gl
 1 31 (41) 23 (35)
P-bilirubin, mean (range), mmoll
 1 9.1 (3–28) 9.4 (3–23)
Number of cycles, median (Q1–Q3) 12 (5–16) 12 (8–16)
Response rate CR+PR, n (%) 29 (39) 38 (58)
Progression-free survival (PFS), median (Q1–Q3) 9.8 (4.2–15.8) 10 (6.5–13.8)
Overall survival (OS), median (Q1–Q3) 17.1 (10.9–24.7) 20.5 (15.1–27.3)
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entire Nordic VI study, PFS and OS did not differ signifi-
cantly between the treatment groups, but the response to
treatment was better in the Lv5FU2-Iri group (58 vs 39%
responders, P¼0.03). Toxicity did not differ according to
randomization arm. The distribution of number of cycles
given is shown in Table 2. The median number of cycles was
12 in both groups. The distribution of different genotypes is
shown in Table 3. The concordance between the six
duplicate DNAs from blood and intestine that were analysed
for UGT1A1, ABCB1 and MTHFR was complete. Genotype
distribution did not differ significantly between the two
randomization arms. Thus, corrections for randomization
did not change any of the results of the statistical analyses.
No significant deviation from Hardy–Weinberg equilibrium
was observed. DNA from paraffin-embedded tissues was
frequently too degraded to be genotyped with the TYMS
method that requires large DNA fragments. The number of
patients successfully genotyped for TYMS was therefore
fewer than for the other genes.
Clinically relevant early toxicity
Clinically relevant early toxicity (outcome A) defined as
grade 3–4 toxicity except alopecia or X20% dose reduction
of the following cycle or toxicity leading to 45 days delay or
discontinuation of treatment after the first one–two cycles,
was recorded in 35 patients (25%). Grade 3–4 toxicity (except
alopecia) was noted in 16 patients, the dose was reduced for
25 patients, and treatment was delayed or discontinued in
10 patients. Eighteen of these patients had neutropenia, 10
had diarrhoea and 21 had other types of toxicity. Patients
who experienced clinically relevant early toxicity in total
received significantly fewer treatment cycles (Po0.001,
Table 2). Among patients who received 1–8 cycles, the OR
for outcome A was 9.37 (95% confidence interval
(CI)¼2.92–30.1) compared with patients who received
413 treatment cycles.
Correlations between genetic variability in UGT1A1,
ABCB1, TYMS and MTHFR and clinically relevant early
toxicity are shown in Figure 1a and Table 3. The risk of
outcome A was significantly increased in patients carrying
UGT1A1*28/*28 compared with patients without *28,
OR¼4.43 (95% CI¼1.30–15.2). The individual outcome A
toxicity that reached statistical significance in *28 homo-
zygotes was neutropenia, OR¼6.87 (95% CI¼1.70–27.7,
Table 4). A high risk of outcome A toxicity other than
neutropenia and diarrhoea was also observed in *28
homozygotes, OR¼3.87 (95% CI¼1.05–14.2).
The risk of clinically relevant early toxicity was signifi-
cantly increased in carriers of the ABCB1 3435 T/T genotype,
OR¼3.79 (95% CI¼1.09–13.2, Table 3). Outcome A was
experienced by 40% of the patients homozygous for the
ABCB1 1236T–2677T–3435T haplotype, but only by 8% of
the homozygotes for the ABCB1 1236C-2677G-3435C haplo-
type (P¼0.036). The incidence of outcome A was decreased
in MTHFR 677 heterozygotes compared with C/C and T/T
(P¼0.005, Table 3). Outcome A did not differ significantly
between different MTHFR 677–1298 haplotypes (P¼0.069).
Outcome A was more frequent in patients heterozygous for
TYMS*2/*3, OR¼3.40 (95% CI¼1.03–11.3, Table 3).
The risk of toxicity was increased in patients with low
haemoglobin at baseline (o130gl
 1 in men, o120gl
 1 in
women), P¼0.015, OR¼2.76 (95% CI¼1.18–6.60). We did
not detect any significant differences in outcome A accord-
ing to age, gender, baseline alkaline phosphatase or bilirubin
levels, WHO performance status, number of metastatic sites
or whether the primary tumour was removed or not (data
not shown).
Overall toxicity
Overall toxicity (outcome B) defined as any grade 3–4
toxicity except alopecia during the entire course of therapy
was seen in 65 patients (46%), most commonly diarrhoea
and neutropenia. In this Nordic VI substudy, neutropenia
grade 3–4 was equally distributed among patients rando-
mized to FLIRI and Lv5FU2-Iri (7% in both groups). There
was no correlation between outcome B and the number of
treatment cycles (Table 2). Nor did we detect any correlation
between outcome B and the explored genetic variants
(Figure 1b).
Response
Sixty-seven patients (48%) responded completely (CR) or
partially (PR) to the treatment, whereas 73 patients (52%)
Table 2 Grade 3–4 toxicity, dose delay, dose reduction or discontinuation after the first two cycles (outcome A) and grade 3–4
toxicity after all cycles (outcome B) in relation to the number of treatment cycles
All Toxicity (%) No toxicity (%) OR (95% CI) P-value
a
Outcome A
1–8 cycles 49 22 (45) 27 (55) 9.37 (2.92–30.1) o0.001
9–13 cycles 41 9 (22) 32 (78) 3.23 (0.92–11.4)
413 cycles 50 4 (8) 46 (92) Ref.
Outcome B
1–8 cycles 49 27 (55) 22 (45) 1.23 (0.56–20.6 ) 0.07
9–13 cycles 41 13 (32) 28 (68) 0.46 (0.20–7.65)
413 cycles 50 25 (50) 25 (50) Ref.
aFisher’s exact test.
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early toxicity (outcome A) in total received fewer treatment
cycles than others (Po0.001, Table 2). Naturally, patients
who received fewer treatment cycles responded less well
to treatment. Non-responders (SDþPD) had been given a
median of 8 cycles, whereas responders (CRþPR) had been
given a median of 14 cycles (mean difference 5.7 cycles,
Po0.001). Of patients with outcome A, 28 (80%) became
non-responders and 7 (20%) became responders, whereas
45 (43%) without outcome A became non-responders and
Table 3 Grade 3–4 toxicity, dose delay, dose reduction or discontinuation after the first two cycles (outcome A) in relation
to genotype
Outcome A All Toxicity (%) No toxicity (%) OR (95% CI) P-value
a
UGT1A1 (TA)n 0.057
wt/wt 72 15 (21) 57 (79) Ref.
wt/*28 51 13 (25) 38 (75) 1.30 (0.56–3.04)
*28/*28 13 7 (54) 6 (46) 4.43 (1.30–15.2)
Missing data 4 0 (0) 4 (100) NA
UGT1A1 –3279 0.277
wt/wt 49 12 (24) 37 (76) Ref.
wt/*60 58 12 (21) 46 (79) 0.80 (0.32–2.00)
*60/*60 18 7 (39) 11 (61) 1.96 (0.62–6.20)
Missing data 15 4 (27) 11 (73) NA
ABCB1 1236 0.401
C/C 45 8 (18) 37 (82) Ref.
C/T 70 19 (27) 51 (73) 1.72 (0.68–4.36)
T/T 23 7 (30) 16 (70) 2.02 (0.63–6.53)
Missing data 2 1 (50) 1 (50) NA
ABCB1 2677 0.693
G/G 41 8 (20) 33 (80) Ref.
G/T 70 19 (27) 51 (73) 1.54 (0.60–3.91)
T/T 21 7 (33) 14 (67) 2.06 (0.63–6.79)
G/A 2 0 (0) 2 (100) NA
T/A 1 0 (0) 1 (100) NA
Missing data 5 1 (20) 4 (80) NA
ABCB1 3435 0.098
C/C 32 4 (12) 28 (88) Ref.
C/T 71 18 (25) 53 (75) 2.38 (0.73–7.71)
T/T 37 13 (35) 24 (65) 3.79 (1.09–13.2)
Missing data 0 0 0 NA
TYMS repeat 0.113
*2/*2 32 4 (12) 28 (88) Ref.
*2/*3 52 17 (33) 35 (67) 3.4 (1.03–11.3)
*3/*3 29 7 (24) 22 (76) 2.23 (0.58–8.59)
Missing data 27 7 (26) 20 (74) NA
MTHFR 677 0.005
C/C 68 23 (34) 45 (66) Ref.
C/T 63 8 (13) 55 (87) 0.28 (0.12–0.7)
T/T 9 4 (44) 5 (56) 1.57 (0.38–6.4)
Missing data 0 0 0 NA
MTHFR 1298 0.230
A/A 53 11 (21) 42 (79) Ref.
A/C 64 15 (23) 49 (77) 1.17 (0.48–2.82)
C/C 20 8 (40) 12 (60) 2.55 (0.84–7.75)
Missing data 3 1 (33) 2 (67) NA
aFisher’s exact test for all non-missing genotypes.
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non-response in patients with outcome A was 5.33 (95%
CI¼2.14–13.3). In retrospect, outcome A had occurred
among 38% of the non-responders and 10% of the
responders (Po0.001). During the entire treatment, non-
responders experienced toxicity Xgrade 3 (outcome B) more
frequently than responders (50 vs 39%, P¼0.05). Nearly all
patients experienced toxicity Xgrade 2 (other than alopecia)
at some time during treatment, and this distribution was
equal between non-responders and responders (88 vs 87%,
P¼0.90).
Patients who carried variant alleles of ABCB1 tended to
respond less well to treatment (Figure 2a). Carriers of at least
o n eT / Tg e n o t y p eo fABCB1 1236, 2677 or 3435 were less likely
to respond to treatment, OR¼0.32 (95% CI¼0.11–0.91).
A post hoc analysis showed that fewer patients with at least one
ABCB1 1236T-2677T-3435T haplotype responded to treatment
compared with others (43 vs 67%, P¼0.027). No other genes
were associated with response. There was no difference in the
number of treatment cycles between genotypes.
OS and PFS
The mean follow-up time was 20 months. PFS was reduced
in ABCB1 2677 heterozygotes, HR¼1.65 (95% CI¼1.08–
2.53) and so was OS, HR¼1.81 (95% CI¼1.12–2.92, Figures
3b and c). OS was decreased in carriers of at least one T/T
genotype of ABCB1 1236, 2677 or 3435 compared with
others, HR¼1.99 (95% CI¼1.07–3.70). A post hoc analysis
showed that OS was decreased in patients with at least one
ABCB1 1236T-2677T-3435T haplotype compared with
others, P¼0.044, OR¼1.56 (95% CI¼1.01–2.45) Figure 3
illustrates that the probability of survival for each of the
ABCB1 1236, 2677 and 3435 genotypes. No other genes
correlated with PFS or OS (Figures 2b and c).
Discussion
Irinotecan is an important medication for the treatment of
metastatic colorectal cancer, but its use is impeded by a
comparably high incidence of unpredictable severe toxi-
city.
1 A number of studies have attempted to explain this
Table 4 Grade 3–4 toxicity, dose delay, dose reduction or
discontinuation after the first two cycles (outcome A) in
relation to UGT1A1*28 divided into neutropenia, diarrhoea
and toxicity other than neutropenia or diarrhoea
Outcome A Neutropenia Diarrhoea Other toxicity
UGT1A1 (TA)n OR (95% CI) OR (95% CI) OR (95% CI)
wt/wt Ref. Ref. Ref.
wt/*28 1.75 (0.55–5.56) 1.85 (0.47–7.25) 0.83 (0.28–2.44)
*28/*28 6.87 (1.70–27.7) 1.42 (0.15–13.8) 3.87 (1.05–14.2)
Odds Ratio
Outcome A
*28/*28
wt/*28
wt/wt
UGT1A1 (TA)n
*60/*60
wt/*60
wt/wt
UGT1A1 −3279
T/T
C/T
C/C
ABCB1 1236
G/A + T/A
T/T
G/T
G/G
ABCB1 2677
T/T
C/T
C/C
ABCB1 3435
*3/*3
*2/*3
*2/*2
TYMS 28 bp repeat
T/T
C/T
C/C
MTHFR 677
C/C
A/C
A/A
MTHFR 1298
Outcome B
012345
Odds Ratio
012345
Ref.
Ref.
Ref.
Ref.
Ref.
Ref.
Ref.
Ref.
Figure 1 Odds ratios with 95% confidence limits for clinically relevant toxicity by genotype. (a) Outcome A: Grade 3–4 toxicity after cycle 1 or 2,
delay or dose reductions of cycle 2 or 3. (b) Outcome B: Worst grade 3–4 toxicity, all cycles.
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pathways.
38 In an exploratory study, we tested whether
variability in selected genes was associated with toxicity,
response and survival in a clinical trial of irinotecan and
5-FU. Patients with metastatic colorectal cancer were
recruited for the trial between 2001 and 2004, and geno-
typing of UGT1A1, ABCB1, TYMS and MTHFR was performed
retrospectively.
In agreement with most earlier studies,
22 we found an
increased risk of early irinotecan-induced toxicity, and
especially neutropenia, in patients homozygous for the
UGT1A1 *28 variant.
8 Patients carrying ABCB1 variant
genotypes and haplotypes tended to have more toxic
reactions, to respond less well to treatment and to die
earlier. Bearing previous conflicting results concerning
ABCB1 and irinotecan in mind,
21,31–34 these findings need
to be confirmed in larger studies. Other associations were
weak, apart from the puzzling low toxicity in carriers of
MTHFR 677 C/T, which would suggest a heterozygous
advantage.
The most convincing results in our and earlier studies of
the pharmacogenetics of irinotecan relate to homozygosity
Odds Ratio
Non response
*28/*28
wt/*28
wt/wt
UGT1A1 (TA)n
*60/*60
wt/*60
wt/wt
UGT1A1 −3279
T/T
C/T
C/C
ABCB1 1236
G/A + T/A
T/T
G/T
G/G
ABCB1 2677
T/T
C/T
C/C
ABCB1 3435
*3/*3
*2/*3
*2/*2
TYMS 28 bp repeat
T/T
C/T
C/C
MTHFR 677
C/C
A/C
A/A
MTHFR 1298
Hazard Ratio
Progression Death
Ref.
Ref.
Ref.
Ref.
Ref.
Ref.
Ref.
Ref.
0 12345 0 12345
Hazard Ratio
0 12345
Figure 2 (a) Odds ratios with 95% confidence limits for non-response (SDþPD) by genotype. (b) Hazard ratios with 95% confidence limits for
the risk of progression or death by genotype. (c) Hazard ratios with 95% confidence limits for the risk death by genotype.
ABCB1 1236
Time (months)
0
0.2
0.4
0.6
0.8
1
0
0.2
0.4
0.6
0.8
1
0
0.2
0.4
0.6
0.8
1
S
u
r
v
i
v
a
l
 
p
r
o
b
a
b
i
l
i
t
y
C/C
C/T
T/T
No. At Risk C/C
70 C/T
23 T/T
ABCB1 2677
Time (months)
G/G
G/T
T/T
41 G/G
70 G/T
21 T/T
ABCB1 3435
Time (months)
C/C
C/T
T/T
32 C/C
71 C/T
37 T/T 23 19 17 12 8 5
65 61 50 44 28 19
45 40 39 37 34 28 20
048 12 16 20 24 048 12 16 20 24 0 4 8 12 16 20 24
21 16 16 13 85
65 62 50 43 28 19
37 36 34 32 26 18
33 28 25 22 11 8
66 62 52 43 32 21
30 30 28 26 22 16
Figure 3 Kaplan–Meier survival curves showing the probability of survival for different ABCB1 genotypes. (a) ABCB1 1236C4T. (b) ABCB1 2677G4T/A.
(c) ABCB1 3435C4T.
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gic toxicity in patients treated with medium-to-high doses.
22
This research has led the US Food and Drug Administration
to change the label for irinotecan to encourage lower initial
doses in patients homozygous for UGT1A1*28 (http://
www.fda.gov/medwatch/SAFETY/2005). In the Nordic VI
study, patients who reacted with early irinotecan toxicity at
a certain level had their subsequent doses delayed or
reduced. Rules for dose reductions and delays were defined
in the clinical trial protocol and were similar to those in
other first-line studies of metastatic colorectal cancer. These
dose adjustments correct for a low clearance of irinotecan
and probably explain why overall toxicity and response did
not differ between UGT1A1 genotypes.
The association between clinically relevant early toxicity,
fewer treatment cycles and worse prognosis found in this
study indicates that it is important to avoid severe initial
toxicity. The magnitude of this correlation surprised us, and
emphasizes the importance of genotyping UGT1A1 to
enable dose adjustments before starting irinotecan therapy.
There is no consensus concerning dose adjustments in
patients homozygous for UGT1A1*28/*28, but a reduction
by 20–40% seems appropriate, with a rapid dose escalation if
adverse effects above grade 1 are not seen. A similar dose
escalation was tested in a randomized phase II trial using
single-drug irinotecan as third-line treatment, albeit without
knowledge of UGT1A1 genotype.
48 An initial dose of
250mgm
 2 was given every third week, as opposed to
350mgm
 2, with an escalation to 350–500mgm
 2 in the
absence of toxicity above grade 1. This lower dose schedule
diminished early severe toxicity, but patients without the
UGT1A1*28/*28 genotype may risk suboptimal dosing
initially and lower response.
Severe irinotecan toxicity was observed in a few patients
with Gilbert’s syndrome already in 1997.
4 With the inten-
tion to avoid participants with Gilbert’s syndrome, patients
with elevated bilirubin were excluded from the Nordic VI
trial. In our study, 13 (9%) of the patients had UGT1A1*28/
*28, which corresponds with the 7–10% background
incidence of Gilbert’s syndrome in Norway and Sweden.
49,50
Evidently, Gilbert’s syndrome was not avoided by excluding
patients with elevated baseline bilirubin in this study, nor
was there any association between baseline bilirubin and
toxicity. The only clinical baseline laboratory value that
predicted toxicity was low haemoglobin. The exclusion of
patients with markedly pathological laboratory values or
poor performance status from the Nordic VI trial may
explain why no other correlation was found.
51
We recognize limitations of our study. First, the sample
size is too small to drive final conclusions. Second, we did
not correct for multiple comparisons, and all results should
be considered as exploratory. Third, there was a non-random
pattern of missing genotypes of TYMS, because of a low
success rate when genotyping DNA from biopsies. This lead
to a bias for patients that were alive and could provide blood
samples, in essence, responders. Considering these limitations,
it is not possible to make any firm conclusions from this
study alone. We therefore look forward to participating in
the International Severe Irinotecan Neutropenia Consor-
tium (http://www.pharmgkb.org/views/project.jsp?pId¼69).
Similarly to the International Warfarin Pharmacogenetics
Consortium,
52 this consortium will pool data on patients
from several studies into a single repository, to increase
sample sizes for investigating the genetic bases of outcomes.
In conclusion, we found a novel association between
ABCB1 variant genotypes and early toxicity, less response
and shorter survival. We confirmed an increased risk of early
irinotecan toxicity, particularly neutropenia, in colorectal
cancer patients carrying UGT1A1*28/*28. The association
between early toxicity, fewer treatment cycles and worse
prognosis indicates that it is important to avoid severe
initial toxicity. However, to find out whether it is beneficial
to follow the FDA recommendation to adjust irinotecan
doses according to UGT1A1 genotype, a prospective trial
needs to be conducted, with a regular dosing arm and an
intervention arm.
Abbreviations
ABCB1 ATP-binding cassette gene B1
CI confidence interval
CPT-11 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-
camptothecin
CR complete response
FA folic acid
FLIRI bolus 5-FU/FA schedule plus irinotecan
5-FU 5-fluorouracil
HR hazard ratio
i.v. intravenous
Lv5FU2-
IRI
bolus/infused de Gramont 5FU/FA schedule plus irinotecan
MDR1 alternate name for ATP-binding cassette gene B1
MTHFR methylenetetrahydrofolate reductase gene
OR odds ratio
OS overall survival
PD progressive disease
PFS progression-free survival
PR partial response
RECIST response evaluation criteria in solid tumours
Q1 1st quartile
Q3 3rd quartile
SD stable disease
SN-38 7-ethyl-10-hydroxy-camptothecin
SNP single nucleotide polymorphism
TOP1 topoisomerase 1
TYMS thymidylate synthase (TS) gene
UGT1A1 the UDP-glucuronosyltransferase 1A1 gene
UGT1A7 the UDP-glucuronosyltransferase 1A7 gene
UGT1A9 the UDP-glucuronosyltransferase 1A9 gene
UNL upper normal limit
Wt wild type
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